{"id":"cisplatin-vinorelbine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"30-50","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication and transcription. Vinorelbine is a semi-synthetic vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, halting cell division. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:04.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT07450508","phase":"PHASE3","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-30","conditions":"Classical Hodgkin Lymphoma Relapsed","enrollment":88},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT03456076","phase":"PHASE3","title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-08-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":257},{"nctId":"NCT04648033","phase":"PHASE1","title":"Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-12-07","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT05553782","phase":"EARLY_PHASE1","title":"Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-01","conditions":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck","enrollment":30},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07131345","phase":"PHASE1, PHASE2","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2025-09-01","conditions":"Malignant Mesothelioma, Mesothelioma","enrollment":55},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT00354393","phase":"PHASE2","title":"Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2002-08","conditions":"Malignant Mesothelioma","enrollment":9},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT05487391","phase":"PHASE3","title":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-12-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":632},{"nctId":"NCT05583188","phase":"PHASE4","title":"Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC","status":"TERMINATED","sponsor":"Galvanize Therapeutics, Inc.","startDate":"2023-02-01","conditions":"NSCLC","enrollment":5},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT02974426","phase":"PHASE3","title":"To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer Stage IIIA, Radiotherapy","enrollment":132},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT02118415","phase":"PHASE2","title":"Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2014-03","conditions":"NSCLC Stage IIIA/B","enrollment":13},{"nctId":"NCT02465736","phase":"PHASE3","title":"Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-07","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":610},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT05248022","phase":"NA","title":"Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2024-02-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":98},{"nctId":"NCT04265274","phase":"PHASE2","title":"Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.","status":"WITHDRAWN","sponsor":"National Cancer Institute, Slovakia","startDate":"2020-01-01","conditions":"Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT04848454","phase":"PHASE2","title":"Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2021-11-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response","enrollment":30},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT03891173","phase":"PHASE2","title":"A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma","status":"TERMINATED","sponsor":"Helix BioPharma Corporation","startDate":"2019-02-19","conditions":"Lung Adenocarcinoma","enrollment":9},{"nctId":"NCT01118676","phase":"PHASE1","title":"Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2010-03","conditions":"Locally Advanced Non Small Cell Lung Cancer (NSCLC)","enrollment":14},{"nctId":"NCT03770299","phase":"PHASE2","title":"An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-01-15","conditions":"Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA","enrollment":""},{"nctId":"NCT04389073","phase":"PHASE2","title":"Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT02985658","phase":"","title":"Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"University of Washington","startDate":"","conditions":"Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer","enrollment":""},{"nctId":"NCT02448797","phase":"PHASE3","title":"Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2015-06-08","conditions":"Non-small Cell Lung Cancer","enrollment":320},{"nctId":"NCT02644252","phase":"PHASE3","title":"Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer","status":"TERMINATED","sponsor":"Vejle Hospital","startDate":"2016-01","conditions":"Lung Cancer","enrollment":79},{"nctId":"NCT00302003","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-02","conditions":"Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma","enrollment":287},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT04342936","phase":"PHASE3","title":"Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-17","conditions":"Classical Hodgkin Lymphoma","enrollment":56},{"nctId":"NCT02977169","phase":"PHASE2","title":"To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"Non-small Cell Lung Cancer Stage IIIA, Radiotherapy","enrollment":300},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT00002583","phase":"PHASE3","title":"Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1994-07-07","conditions":"Lung Cancer","enrollment":482},{"nctId":"NCT02985203","phase":"PHASE2","title":"Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-11","conditions":"Lung Neoplasm Malignant","enrollment":45},{"nctId":"NCT01405079","phase":"PHASE3","title":"Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2011-09-19","conditions":"Non-small Cell Lung Cancer","enrollment":222},{"nctId":"NCT00003400","phase":"PHASE2","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1998-09","conditions":"Prostate Cancer","enrollment":45},{"nctId":"NCT02603003","phase":"PHASE1","title":"the\"Fuzheng\" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2015-06","conditions":"Non-small Cell Lung Cancer(NSCLC)","enrollment":218},{"nctId":"NCT00349089","phase":"PHASE2","title":"Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy","status":"COMPLETED","sponsor":"Thoraxklinik-Heidelberg gGmbH","startDate":"2006-09-26","conditions":"Non Small Cell Lung Cancer","enrollment":132},{"nctId":"NCT00198367","phase":"PHASE2","title":"Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2003-01","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT03381066","phase":"PHASE3","title":"A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-04-10","conditions":"Completely Resected NSCLC With Common EGFR Mutations","enrollment":225},{"nctId":"NCT00064077","phase":"PHASE3","title":"Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2003-05","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":513},{"nctId":"NCT03656393","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2018-08-31","conditions":"NSCLC, EGFR","enrollment":48},{"nctId":"NCT01443078","phase":"PHASE2","title":"Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-10","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT01029678","phase":"PHASE2","title":"Concomitant Radio-chemotherapy in the Elderly","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2010-01","conditions":"Non Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT03423849","phase":"PHASE2, PHASE3","title":"The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2018-02-08","conditions":"Breast Cancer, Chemotherapy Effect, Disease-free Survival","enrollment":200},{"nctId":"NCT02919462","phase":"PHASE2","title":"Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-03","conditions":"Carcinoma, Non-Small-Cell Lung, Secondary, Advanced Stage IIIB","enrollment":2},{"nctId":"NCT02777788","phase":"PHASE2, PHASE3","title":"Curative Study of Chinese Traditional Medicine to Treat Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2014-09","conditions":"Cancer","enrollment":120},{"nctId":"NCT00985855","phase":"PHASE2","title":"Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Institut de Cancérologie de la Loire","startDate":"2009-09","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":91},{"nctId":"NCT01104259","phase":"PHASE1","title":"Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-07","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1","enrollment":50},{"nctId":"NCT00455572","phase":"PHASE1","title":"Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05-11","conditions":"Lung Cancer, Non-Small Cell","enrollment":71},{"nctId":"NCT03117335","phase":"PHASE3","title":"Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.","startDate":"2011-11-10","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":560},{"nctId":"NCT00863512","phase":"PHASE3","title":"Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-03","conditions":"Lung Cancer","enrollment":34},{"nctId":"NCT01216527","phase":"PHASE3","title":"Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-06","conditions":"Squamous Cell Esophageal Carcinoma","enrollment":430},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT00842712","phase":"PHASE2","title":"Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":232},{"nctId":"NCT02795884","phase":"PHASE3","title":"Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2016-06","conditions":"NSCLC","enrollment":""},{"nctId":"NCT02940990","phase":"PHASE2","title":"SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2016-11","conditions":"NSCLC, SBRT, GM-CSF","enrollment":50},{"nctId":"NCT00642824","phase":"PHASE2","title":"A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT00773188","phase":"PHASE1","title":"A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":6},{"nctId":"NCT02579564","phase":"PHASE3","title":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2016-10","conditions":"Malignant Hydrothorax, Non Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT01683175","phase":"PHASE2","title":"Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-08","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":94},{"nctId":"NCT00683514","phase":"PHASE3","title":"Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2005-04","conditions":"NSCLC","enrollment":201},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":"Lymphoma","enrollment":442},{"nctId":"NCT00496275","phase":"PHASE1","title":"Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-08","conditions":"Non Small Cell Lung Cancer","enrollment":17},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00686959","phase":"PHASE3","title":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":598},{"nctId":"NCT02720614","phase":"PHASE2","title":"Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"LIN QIANG","startDate":"2012-05","conditions":"Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT00198432","phase":"PHASE2","title":"Chemoradiotherapy of NSCLC Stage IIIB","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2002-03","conditions":"NSCLC Stage IIIB, Concomitant Radiochemotherapy","enrollment":130},{"nctId":"NCT00659269","phase":"PHASE3","title":"A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Cancer","enrollment":319},{"nctId":"NCT02665702","phase":"PHASE2","title":"Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":76},{"nctId":"NCT00401609","phase":"PHASE1, PHASE2","title":"G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2000-11","conditions":"Small Cell Lung Cancer","enrollment":85},{"nctId":"NCT01109524","phase":"PHASE2","title":"Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-07","conditions":"Lung Neoplasms, Carcinoma, Cancer of the Lung","enrollment":72},{"nctId":"NCT00675597","phase":"NA","title":"Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-05","conditions":"Lung Cancer","enrollment":25},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT02544243","phase":"PHASE2","title":"Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT01843647","phase":"PHASE2","title":"Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-04","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT02497118","phase":"PHASE4","title":"Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT02083211","phase":"PHASE3","title":"Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2010-07","conditions":"Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment","enrollment":168},{"nctId":"NCT01209520","phase":"NA","title":"Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-07","conditions":"Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation","enrollment":6},{"nctId":"NCT00661011","phase":"PHASE2","title":"Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy","status":"TERMINATED","sponsor":"European Lung Cancer Working Party","startDate":"2007-01","conditions":"Non Small Cell Lung Carcinoma","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":167,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cisplatin + vinorelbine","genericName":"cisplatin + vinorelbine","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}